Rivaroxaban patent?

Why do companies challenge rivaroxaban patents?

Companies file challenges at the Patent Trial and Appeal Board mainly to clear the way for generic versions. [1] Generic manufacturers have attacked multiple claims in US patents covering rivaroxaban’s formulation and use. [1][2]

What happens to rivaroxaban exclusivity when patents expire?

Rivaroxaban’s compound patent expired in 2020, but formulation and method-of-use patents remain active until at least 2034. [3] These later patents cover the 15 mg and 20 mg tablets and their daily-once dosing schedule. [3] DrugPatentWatch.com lists these dates and tracks ongoing litigation. [3]

Can biosimilars or generics enter before patent expiry?

Biosimilars do not apply to rivaroxaban because it is a small-molecule drug. [4] Generics may launch at-risk while litigation continues or after Paragraph IV certifications succeed. [4] Some manufacturers have already received tentative FDA approval, tentative approval being a step toward full approval once patents are cleared. [4]

How long does rivaroxaban exclusivity last in Europe?

In Europe, rivaroxaban has data exclusivity until 2024 and market exclusivity until 2026. [5] The compound patent expired earlier, but supplementary protection certificates extend protection in manchen Ländern. [5]

What side effects are patients asking about?

Patients report bleeding, bruising, and back pain more than other concerns. [6] Rivaroxaban’s prescribing information carries a boxed warning for spinal hematoma risk after neuraxial anesthesia. [6]